TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8894060

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 1837776

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 664
Study: 6136288

Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) lorazepam
Number of subjects: 150
Study: 31484004

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Glue)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control (stapler or manual suture only)
Number of subjects: 189
Study: 30401369

Group type: EXPERIMENTAL
Intervention: Opsite combined with wet gauze (normal saline group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Opsite combined with wet gauze and eye ointment (ointment group)
Number of subjects: 41
Study: 26329135

Group type: EXPERIMENTAL
Intervention: Total cruciferous vegetable intake
Number of subjects: 54
Study: 24444360

Group type: EXPERIMENTAL
Intervention: Umbilical vein injection of 800 mcg misoprostol dissolved in 20 mL of normal saline
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group receiving 20 mL of normal saline
Number of subjects: 46
Study: 22399327

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 215

Group type: COMPARATOR
Intervention: In-person counseling
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Affected participants
Number of subjects: 215

Group type: COMPARATOR
Intervention: Non-affected participants
Number of subjects: 215

Group type: COMPARATOR
Intervention: Both groups (affected and non-affected)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Telephone pre-counseling
Number of subjects: 215
Study: 20231061

Group type: EXPERIMENTAL
Intervention: Consolidation docetaxel (CD)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Observation (OB)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 243
Study: 17711616

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 4308

Group type: COMPARATOR
Intervention: Current asthma therapy (control)
Number of subjects: 4308
Study: 15966467

Group type: COMPARATOR
Intervention: Glimepiride/Specifar (test preparation)
Number of subjects: 24
Study: 12472990

Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local antibiotic therapy combined with scaling and root planing
Number of subjects: 0
Study: 9461137

Group type: EXPERIMENTAL
Intervention: Patients with significant hypesthesia (23 patients, 19.8% identified with monofilaments; 29 patients, 25.0% identified with brush strokes)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Patients without significant hypesthesia
Number of subjects: 116
Study: 8589139

Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin (IVIG) prophylaxis
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole prophylaxis
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study: 2220915

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2.0 gm of elemental calcium as calcium carbonate)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 387330

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 18
Study: 31628486

Group type: EXPERIMENTAL
Intervention: COMBO (continuing csDMARD therapy)
Number of subjects: 125

Group type: COMPARATOR
Intervention: MONO (withdrawing csDMARD therapy)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: COMBO
Number of subjects: 125

Group type: COMPARATOR
Intervention: MONO
Number of subjects: 125
Study: 30501015

Group type: EXPERIMENTAL
Intervention: Upward contrast social comparisons (SCs)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Upward identification social comparisons (SCs)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Downward identification social comparisons (SCs)
Number of subjects: 240
Study: 28183505

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 2098

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 2098

Group type: EXPERIMENTAL
Intervention: Both stent types
Number of subjects: 2098
Study: 25892082

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dihydralazine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nicardipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketanserin and Dihydralazine
Number of subjects: 30
Study: 22343209

Group type: EXPERIMENTAL
Intervention: Usual care plus patient activation intervention (n = 43)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual care (n = 41)
Number of subjects: 84
Study: 20410322

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19474512

Group type: EXPERIMENTAL
Intervention: R-CHOP therapy (rituximab combined with cyclophosphamide, doxorubicin, vincristine, and predonisolone)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (N=10)
Number of subjects: 7
Study: 17265094

Group type: EXPERIMENTAL
Intervention: HES preload group (15 ml x kg(‐1) before spinal anesthesia, n = 18)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HES coload group (15 ml x kg(‐1) after induction of spinal anesthesia, n = 18)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no rapid infusion, n = 18)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HES preload group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HES coload group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 54
Study: 14966821

Group type: EXPERIMENTAL
Intervention: Respimat SMI 10/25
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Respimat SMI 20/50
Number of subjects: 535

Group type: COMPARATOR
Intervention: CFC-MDI 40/100
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Respimat SMI
Number of subjects: 535
Study: 11739069

Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release (100 mg-300 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Paroxetine (10 mg-40 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bupropion and Paroxetine (combined)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Remitters (compared to Partial Responders and Nonresponders)
Number of subjects: 100
Study: 10195027

Group type: EXPERIMENTAL
Intervention: Patient Delivered Partner Medication (PDPM)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Partner Referral Cards (Control)
Number of subjects: 178
Study: 7842362

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms aqueous nasal spray twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo spray
Number of subjects: 0
Study: 3170392

Group type: EXPERIMENTAL
Intervention: Single daily dose of netilmicin plus metronidazole
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thrice daily dose of netilmicin plus metronidazole
Number of subjects: 40
Study: 29993976

Group type: EXPERIMENTAL
Intervention: Improved Space Forest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original versions of bagging, random forest, and rotation forest
Number of subjects: 0
Study: 27964843

Group type: EXPERIMENTAL
Intervention: Pertuzumab in addition to trastuzumab and docetaxel
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo in addition to trastuzumab and docetaxel
Number of subjects: 808
Study: 24737406

Group type: EXPERIMENTAL
Intervention: Combined treatment group (UPPP + Oral Appliance)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pure surgery group (UPPP)
Number of subjects: 40
Study: 23161360

Group type: EXPERIMENTAL
Intervention: 3 ml ropivacaine 0.75% plus 20 µg dexmedetomidine (RpD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 3 ml ropivacaine 0.75% (R)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3 ml ropivacaine 0.75% plus systemic 20 µg dexmedetomidine (RsD)
Number of subjects: 36
Study: 21574873

Group type: EXPERIMENTAL
Intervention: Low dose of l-arginine (0.075 g·kg(‐1) of body mass)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High dose of l-arginine (0.15 g·kg(‐1) of body mass)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low and High dose of l-arginine
Number of subjects: 14
Study: 19771282

Group type: EXPERIMENTAL
Intervention: Pickle juice
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CHO-e drink
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study: 17027233

Group type: EXPERIMENTAL
Intervention: Konjac glucomannan (KGM) 1.5 g/meal, 4.5 g/d for 21 days
Number of subjects: 8
Study: 15617456

Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg once daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: enalapril 10 mg once daily
Number of subjects: 147
Study: 11532240

Group type: EXPERIMENTAL
Intervention: MRI intervention group
Number of subjects: 118

Group type: COMPARATOR
Intervention: No-MRI intervention group
Number of subjects: 118
Study: 9406013

Group type: COMPARATOR
Intervention: MRX-115 (lipid-encapsulated perfluoropropane gas microbubbles)
Number of subjects: 48
Study: 8328575

Group type: EXPERIMENTAL
Intervention: Triazolam plus behavioral therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Triazolam plus sleep-related information
Number of subjects: 15
Study: 3016071

Group type: EXPERIMENTAL
Intervention: Secretin (1 CU/kg/h, 0-120 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Secretin (1 CU/kg/h, 0-120 min) + Cholecystokinin (CCK) (1 IU/kg/h, 60-120 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (NaCl infusion study)
Number of subjects: 10
Study: 29313359

Group type: COMPARATOR
Intervention: Attention control (physical activity recommendations)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: High-volume MICT (45 minutes of moderate-intensity continuous training, 2 days/week)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: High-volume HIIT (2 days/week)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Low-volume HIIT (20 minutes, 2 days/week)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: High-volume MICT
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: High-volume HIIT
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Low-volume HIIT
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Medication management
Number of subjects: 175
Study: 27616034

Group type: EXPERIMENTAL
Intervention: Ergoferon
Number of subjects: 156

Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 156
Study: 24048736

Group type: COMPARATOR
Intervention: Clinical parameters alone
Number of subjects: 550

Group type: COMPARATOR
Intervention: Urine peptide biomarkers (FGA1826, FGA1883, FGA2659)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Ensemble model combining clinical parameters with urine biomarkers
Number of subjects: 550
Study: 22527984

Group type: EXPERIMENTAL
Intervention: Omega-6/omega-3 fatty acid ratio >15
Number of subjects: 80

Group type: COMPARATOR
Intervention: Folate <5 ug/L
Number of subjects: 80

Group type: COMPARATOR
Intervention: 25‐hydroxy vitamin D <20 ng/mL
Number of subjects: 80
Study: 21275160

Group type: EXPERIMENTAL
Intervention: Chinese medicine and general stroke-treatment (135 patients)
Number of subjects: 377

Group type: COMPARATOR
Intervention: General stroke-treatment only (126 patients)
Number of subjects: 377
Study: 18848094

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 47710

Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 47710

Group type: COMPARATOR
Intervention: Benzodiazepine/narcotics
Number of subjects: 47710

Group type: EXPERIMENTAL
Intervention: Propofol (administered by OMS)
Number of subjects: 47710

Group type: EXPERIMENTAL
Intervention: Propofol (administered by non-OMS)
Number of subjects: 47710
Study: 16096449

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel, three times a day during the entire ICU stay
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo gel, three times a day during the entire ICU stay
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel
Number of subjects: 228
Study: 12045487

Group type: EXPERIMENTAL
Intervention: Tenofovir DF 300 mg once-daily
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Tenofovir DF 300 mg therapy
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 11053318

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (citrate)
Number of subjects: 12
Study: 9356491

Group type: EXPERIMENTAL
Intervention: Indinavir (IDV)/Zidovudine (ZDV)/Lamivudine (3TC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Zidovudine (ZDV)/Lamivudine (3TC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Indinavir (IDV)
Number of subjects: 10
Study: 1326582

Group type: EXPERIMENTAL
Intervention: Intranasal interferon‐alpha 2b, ipratropium, and oral naproxen; treatment started 24 hours after inoculation, continued three times a day for 4 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 3887553

Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg twice daily)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 79
Study: 31725463

Group type: EXPERIMENTAL
Intervention: Formative assessment condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Summative assessment condition
Number of subjects: 0
Study: 29676237

Group type: EXPERIMENTAL
Intervention: Ultramicronized palmitoylethanolamide (600 mg twice daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no treatment except surgical therapy)
Number of subjects: 42
Study: 26780107

Group type: EXPERIMENTAL
Intervention: Partial hepatectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: TACE + RFA
Number of subjects: 200
Study: 25577838

Group type: EXPERIMENTAL
Intervention: Transvesical single-site laparoscopic radical prostatectomy (TVSSLRP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nerve-sparing extraperitoneal laparoscopic radical prostatectomy (nsELRP)
Number of subjects: 50
Study: 22445839

Group type: EXPERIMENTAL
Intervention: Risk reduction oriented intervention (yellow light)
Number of subjects: 2120

Group type: EXPERIMENTAL
Intervention: Referral to addiction outpatient clinic (red light)
Number of subjects: 2120

Group type: COMPARATOR
Intervention: Consultation with school nurse or physician
Number of subjects: 2120
Study: 20472498

Group type: EXPERIMENTAL
Intervention: Sildenafil 50mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 19469746

Group type: EXPERIMENTAL
Intervention: PDM training (n = 366 participants)
Number of subjects: 779

Group type: COMPARATOR
Intervention: Bupropion SR (n = 413 participants)
Number of subjects: 779
Study: 15982142

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Individual therapy (IT)
Number of subjects: 176
Study: 12878631

Group type: EXPERIMENTAL
Intervention: Oxygen 50% administration during surgery and for 2 h post-surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxygen 30% administration during surgery and for 2 h post-surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oxygen 50% administration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxygen 30% administration
Number of subjects: 100
Study: 10388309

Group type: EXPERIMENTAL
Intervention: 100 ml of contrast material (iopamidol 300 mgI/ml)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 50 ml of contrast material (iopamidol 300 mgI/ml)
Number of subjects: 150
Study: 8625251

Group type: EXPERIMENTAL
Intervention: Octreotide (SMS 201.995) 500 micrograms 3 times a day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Octreotide (SMS 201.995) 1000 micrograms 3 times a day
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Octreotide (SMS 201.995)
Number of subjects: 58
Study: 30796194

Group type: EXPERIMENTAL
Intervention: Zoledronate (10 courses of 4 mg intravenous infusions)
Number of subjects: 798
Study: 29043927

Group type: EXPERIMENTAL
Intervention: Novel proprietary curcumin liquid droplet micromicellar formulation (CLDM), 400 mg dose, containing 64.6 mg curcumin
Number of subjects: 12

Group type: COMPARATOR
Intervention: 95% curcumin powder in capsule form, 400 mg dose, containing 323 mg curcumin
Number of subjects: 12
Study: 27692279

Group type: EXPERIMENTAL
Intervention: Intravenous normal saline infusion as a bolus of 22 ml/kg body weight (approximately 2 L)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control: intravenous normal saline infusion at a minimal rate to keep the vein open
Number of subjects: 15
Study: 25148841

Group type: EXPERIMENTAL
Intervention: Date palm pollen (DPP) administered orally (2 g daily for 42 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (facility standard of care)
Number of subjects: 20
Study: 21499177

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 88
Study: 18416851

Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure mechanical ventilation (NPPV)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Invasive mechanical ventilation (IMV)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 65
Study: 15722689

Group type: EXPERIMENTAL
Intervention: Knowledge of cholesterol levels
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Knowledge of cholesterol targets
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Knowledge among specific demographics
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Knowledge among patients with risk factors
Number of subjects: 738
Study: 12764232

Group type: EXPERIMENTAL
Intervention: Patients with acute cerebral ischemia
Number of subjects: 92
Study: 10815850

Group type: EXPERIMENTAL
Intervention: Experimental bicarbonate solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 10
Study: 8751396

Group type: EXPERIMENTAL
Intervention: Conformal neutron/photon irradiation (9-10 Neutron + 38 Photon Gy)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Conformal neutron/photon irradiation with neoadjuvant hormonal therapy
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Conformal neutron/photon irradiation without neoadjuvant hormonal therapy
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Functional erections pretreatment
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Nonfunctional erections pretreatment
Number of subjects: 76
Study: 1596562

Group type: EXPERIMENTAL
Intervention: Intermediate-purity, pasteurized FVIII-vWF concentrate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intermediate-purity, dry-heated FVIII-vWF concentrate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Solvent/detergent-treated FVIII-vWF concentrate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-purity solvent/detergent-treated FVIII-vWF concentrate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Solvent/detergent-treated vWF concentrate (containing little FVIII)
Number of subjects: 10
Study: 4070189

Group type: EXPERIMENTAL
Intervention: Cognitive teaching emphasizing factual knowledge
Number of subjects: 1733

Group type: EXPERIMENTAL
Intervention: Affective teaching stressing feelings, attitudes, and values
Number of subjects: 1733

Group type: EXPERIMENTAL
Intervention: Mixed approach combining cognitive and affective features
Number of subjects: 1733

Group type: EXPERIMENTAL
Intervention: All teaching groups
Number of subjects: 1733

Group type: EXPERIMENTAL
Intervention: Affective and cognitive approaches
Number of subjects: 1733
Study: 31995183

Group type: EXPERIMENTAL
Intervention: 7-valent or 13-valent PCV
Number of subjects: 1754
Study: 30844656

Group type: EXPERIMENTAL
Intervention: Sapylin (OK-432)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no Sapylin)
Number of subjects: 120
Study: 29902979

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream, applied intravaginally three times a week for 16 weeks.
Number of subjects: 433

Group type: COMPARATOR
Intervention: Large Loop Excision of the Transformation Zone (LLETZ) treatment, performed according to current guidelines.
Number of subjects: 433
Study: 26841373

Group type: EXPERIMENTAL
Intervention: Single intramuscular injection of 0.03 mg rhTSH
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 40
Study: 24417410

Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 2832

Group type: EXPERIMENTAL
Intervention: Reasoning training
Number of subjects: 2832

Group type: EXPERIMENTAL
Intervention: Speed of processing training
Number of subjects: 2832

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 2832
Study: 23015069

Group type: EXPERIMENTAL
Intervention: PG refinement algorithm
Number of subjects: 310

Group type: COMPARATOR
Intervention: PG algorithm
Number of subjects: 310

Group type: COMPARATOR
Intervention: Fixed dose approach (3 mg/day)
Number of subjects: 310
Study: 21050565

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 32
Study: 17655682

Group type: EXPERIMENTAL
Intervention: Desmopressin MELT (sublingual lyophilisate)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Tablet formulation of desmopressin
Number of subjects: 221
Study: 16177537

Group type: EXPERIMENTAL
Intervention: Laboratory based small angle x-ray scattering (SAXS) using the 'SAXSess' system
Number of subjects: 0
Study: 12665498

Group type: EXPERIMENTAL
Intervention: 200 mg micronized fenofibrate daily
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study: 10372613

Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 39

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 39